DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Use of Levonorgestrel-Releasing Device (Metraplant-E) in the Treatment of Dysfunctional Uterine Bleeding

Information source: Ain Shams Maternity Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Dysfunctional Uterine Bleeding

Intervention: Metraplant-E levonorgestrel-releasing intrauterine device (Device)

Phase: Phase 3

Status: Recruiting

Sponsored by: Ain Shams Maternity Hospital

Official(s) and/or principal investigator(s):
Mohamed Azzam, MD, Study Director, Affiliation: Ain Shams University Faculty of Medicine

Overall contact:
Alshaimaa Mahmoud, MBBch, Phone: 002 01068095083, Email: alshaimaa_mahmoud@yahoo.com

Summary

Research hypothesis: Release of levonorgestrel from Metraplant-E levonorgestrel releasing intrauterine contraceptive device is inadequate to be used as a medical line of treatment of dysfunctional uterine bleeding. The investigators aim to evaluate the therapeutic effect of the intrauterine system (Metraplant-E) in the treatment of dysfunctional uterine bleeding.

Clinical Details

Official title: The Use of Levonorgestrel-Releasing Device (Metraplant-E) in the Treatment of Dysfunctional Uterine Bleeding

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Amount of menstrual blood loss (MBL) in women with menorrhagia by means of pictorial bleeding assesment chart

Secondary outcome:

Histological changes in Endometrial biopsy prior to and 6 months after the insertion of the intrauterine system (Metraplant-E)

Hemoglobin level in blood prior to the device insertion and 6 months afterwards

Detailed description: Primary outcome : The investigators aim to evaluate the short term release of levonorgestrel from the Metraplant-E levonorgestrel releasing intrauterine contraceptive devices (IUCDs). This is in a trial to determine to what extent the intrauterine release of levonorgestrel would reduce MBL in women with menorrhagia and if the treatment would increase the body iron stores and the degree of patient satisfaction and acceptability of treatment for the patients with dysfunctional uterine bleeding. This will be conducted through a questionnaire offered to the women participating in this study which is designed on Likert scale. Secondary outcome: 1) Endometrial biopsy prior to and 6 months after the insertion of the intrauterine system (Metraplant-E). 3) Haemoglobin level measurement in gm/dl and serum ferritin level on same occasions as when endometrial biopsy is done. 4) The amount of monthly menstrual blood loss after the insertion the Metraplant-E levonorgestrel releasing intrauterine contraceptive devices using the following scores: bleeding index,total bleeding score and Pictorial blood loss assessment chart (PBAC). Inclusion criteria: 1. Women seeking contraception. 2. Women with history of menorrhagia. 3. Pre and perimenopausal women who are married or previously married. 4. Failure of other medical treatment to control menorrhagia such as hemostatics. 5. Women who did not tolerate copper IUD (intrauterine device) due to increased amount of menstrual blood loss which could lead to anemia.

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Female.

Criteria:

Inclusion Criteria: 1. Women seeking contraception. 2. Women with history of menorrhagia. 3. Pre and perimenopausal women who are married or previously married. 4. Failure of other medical treatment to control menorrhagia such as hemostatics. 5. Women who did not tolerate copper IUD due to increased amount of menstrual blood loss which could lead to anemia. Exclusion Criteria: 1. History of ectopic pregnancy . 2. Pregnancy or suspicion of pregnancy. 3. Congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity. 4. Acute pelvic inflammatory disease 5. Postpartum endometritis or infected abortion in the past 3 months. 6. Known or suspected uterine or cervical neoplasia or unresolved, abnormal Pap smear. 7. Genital bleeding of unknown etiology. 8. Untreated acute cervicitis or vaginitis, including bacterial vaginosis or other lower genital tract infections, until infection is controlled. 9. Acute liver disease or liver tumor (benign or malignant). 10. Conditions associated with increased susceptibility to infections with microorganisms. Such conditions include, but are not limited to, leukemia, acquired immune deficiency syndrome (AIDS), and I. V. drug abuse. 11. A previously inserted IUD that has not been removed. 12. Hypersensitivity to any component of this product. 13. Women taking anticoagulants 14. Women with coagulopathies due to thrombocytopenia or platelets dysfunction. 15. Known or suspected carcinoma of the breast.

Locations and Contacts

Alshaimaa Mahmoud, MBBch, Phone: 002 01068095083, Email: alshaimaa_mahmoud@yahoo.com

Ain Shams Maternity Hospital, Cairo, Egypt; Recruiting
Mohamed Azzam, MD, Phone: 002 0103465651
Laila Farid, MD, Phone: 002 01222148471
Alshaimaa Mahmoud, MBBch, Principal Investigator
Additional Information

Starting date: June 2014
Last updated: June 5, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017